Status:
COMPLETED
Survival Study of Docetaxel and Carboplatin as Neo-Adjuvant Vs Adjuvant Chemotherapy in Early Stage NSLC
Lead Sponsor:
Chinese Society of Lung Cancer
Conditions:
Non-small Cell Lung Cancer
Eligibility:
All Genders
18-75 years
Phase:
PHASE3
Brief Summary
The objective of the trial is to determine whether 3 cycles of TP (docetaxel plus cisplatin) after complete operation will improve survival when compared with 3 cycles of TP prior to complete resectio...
Detailed Description
Non-small-cell lung cancer (NSCLC) accounts for approximately 80% of lung cancers diagnosed worldwide. Surgical resection offers the best chance for cure for those patients diagnosed with early-stage ...
Eligibility Criteria
Inclusion
- Histologically or cytologically confirmed stage IB-IIIA non-small cell lung cancer patients,without previous chemotherapy, radiotherapy or target-therapy;
- age from 18 to 75;
- PS with ECOC 0-1;
- Adequate haematological and Hepatic- renal function;
- Expected to live longer than 12 months;
- The informed consent should be signed.
Exclusion
- Patients with Small Cell Lung Cancer;
- Already receiving any prior anti-cancer treatment;
- Pregnant women;
- Uncontrolled diabetes, mental disease;
- Hepatic and renal function failure;
- The investigators believe the patient is not suitable to be enrolled in the study
Key Trial Info
Start Date :
March 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2013
Estimated Enrollment :
410 Patients enrolled
Trial Details
Trial ID
NCT00321334
Start Date
March 1 2006
End Date
December 1 2013
Last Update
August 6 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chinese Society of Lung Cancer
Guangzhou, Guangdong, China, 510080